Primary Sclerosing Cholangitis

Primary Sclerosing Cholangitis (PSC) is a chronic, progressive, cholestatic liver disease characterized by inflammation, obliterative fibrosis, and segmental stricturing of both the intrahepatic and extrahepatic bile ducts. Over time, progressive biliary obstruction leads to biliary cirrhosis, portal hypertension, and hepatic failure. PSC is highly associated with inflammatory bowel disease (IBD), particularly ulcerative colitis, and carries a significantly elevated risk of hepatobiliary and colorectal malignancies.

The exact etiology of PSC remains unknown but is understood to be multifactorial, involving an interplay of genetic susceptibility, immune dysregulation, and environmental triggers.

• Genetic Susceptibility: Strong association with Human Leukocyte Antigen (HLA) class I and II alleles (e.g., HLA-B8, DR3, DRw52a).


• Immune Mechanisms: T-cell mediated destruction of cholangiocytes, supported by the presence of autoantibodies.


• Gut-Liver Axis: The "leaky gut" hypothesis suggests that intestinal bacteria or toxic metabolites translocate across inflamed intestinal mucosa into the portal circulation, triggering hepatic inflammatory pathways.

Ongoing inflammation of the bile duct wall leads to chronic, segmental injury.

• Cellular Level: Infiltration of lymphocytes (primarily T-cells) into the portal tracts, causing destruction of cholangiocytes.


• Tissue Level: Concentric "onion-skin" periductal fibrosis wraps around bile ducts.


• Organ Level: This fibrosing process leads to alternating segments of stricturing and dilation (ectasia) in the biliary tree. Prolonged biliary obstruction results in chronic cholestasis, retentive accumulation of toxic bile acids, progressive parenchymal destruction, lobular collapse, and ultimately, biliary cirrhosis and portal hypertension.

• Prevalence: Approximately 1 to 16 cases per 100,000 individuals, with highest rates in Northern Europe and North America.
• Age: Primarily diagnosed in young to middle-aged adults, typically between 30 and 50 years of age.
• Gender: Strong male predominance, with a male-to-female ratio of roughly 2:1.
• Associated Conditions: Approximately 70–80% of patients with PSC in Western countries have concurrent IBD (most commonly Ulcerative Colitis).

• Male sex
• Age (30–50 years)
• Coexisting Inflammatory Bowel Disease (specifically ulcerative colitis)
• First-degree family history of PSC

• Vital Signs: Normal in chronic states; fever and tachycardia indicate acute bacterial cholangitis.
• Inspection: Jaundice, scleral icterus, skin excoriations (from scratching), cachexia, temporal wasting, and muscle atrophy in advanced disease.
• Palpation: Hepatomegaly (early), splenomegaly (indicating portal hypertension), and RUQ abdominal tenderness.
• Auscultation: Normal bowel sounds; presence of shifting dullness or fluid wave indicates ascites.

• Primary Biliary Cholangitis (PBC): Differentiated by female predominance (9:1), positive Anti-Mitochondrial Antibodies (AMA), and selective destruction of small intrahepatic ducts without extrahepatic involvement.
• IgG4-Related Sclerosing Cholangitis: Differentiated by elevated serum IgG4 levels, systemic manifestations (e.g., autoimmune pancreatitis), and rapid clinical response to corticosteroid therapy.
• Cholangiocarcinoma: Often mimics a dominant PSC stricture. Differentiated by brush cytology, fluorescence in situ hybridization (FISH), or rising carbohydrate antigen 19-9 (CA 19-9) levels.

• Secondary Biliary Cirrhosis and portal hypertension (causing variceal hemorrhage, splenomegaly, and ascites).
• Acute Bacterial Cholangitis (biliary infection behind tight strictures).
• Cholangiocarcinoma (bile duct cancer).
• Colorectal Cancer (in patients with concurrent IBD).
• Metabolic Bone Disease (osteopenia and osteoporosis due to malabsorption of vitamin D).
• Cholelithiasis and Choledocholithiasis (pigment gallstones).

PSC is a progressive disease with a highly variable clinical course.

• Short-Term Outcomes: Good in asymptomatic patients; managed with supportive care.


• Long-Term Outcomes: Poor without liver transplantation. The median survival from diagnosis to death or liver transplantation is approximately 10 to 12 years.


• Malignancy Impact: Approximately 10–15% of patients develop cholangiocarcinoma, which carries an extremely poor prognosis.

• Primary Prevention: None, as the definitive etiology is unknown.
• Secondary Prevention: Regular screening for cholangiocarcinoma (MRCP/ultrasound and CA 19-9) and colonoscopy surveillance starting at the time of PSC diagnosis in patients with IBD.

The following homeopathic remedies have been historically indicated for symptoms associated with Primary Sclerosing Cholangitis. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Primary Sclerosing Cholangitis.